ReachMD

Episodes 1-15 of 15

• • 

    

    Javed Butler, MD, MPH, MBA

    Peer

  • 

    

    Paul W. Armstrong, MD

    Peer

  1

  

  RestartResume

  New Therapies Offer Improved Outcomes in HFrEF Management

  New Therapies Offer Improved Outcomes in HFrEF Management

  0.25 credits

• • 

    

    Jay S. Giri, MD, MPH

    Peer

  • 

    

    Renuka Jain, MD

    Peer

  2

  

  RestartResume

  New Opportunities to Manage Aortic Stenosis with TAVR

  New Opportunities to Manage Aortic Stenosis with TAVR

  0.50 credits

• • 

    

    Eliot Brinton, MD, FAHA, FNLA

    Peer

  • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  17

  

  RestartResume

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  The New Role of Omega-3 Fatty Acids in Reducing ASCVD Risk in Women: Expert Dialogue

  0.75 credits

• • 

    

    Yehuda Handelsman, MD

    Peer

  • 

    

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    Peer

  • 

    

    Om P. Ganda, MD

    Peer

  • 

    

    Jorge Plutzky, MD

    Peer

  • 

    

    Paul D. Rosenblit, MD, PhD, FACE, FNLA

    Peer

  4

  

  RestartResume

  Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

  Hot Topics in Omega-3s and ASCVD Risk Reduction in Diabetes

• • 

    

    Michel Farnier, MD, PhD

    Peer

  • 

    

    Børge G. Nordestgaard, MD, DMSc

    Peer

  8

  

  RestartResume

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl (IPE)

  0.75 credits

• • 

    

    Christopher P. Cannon, MD

    Peer

  • 

    

    Samuel Dagogo-Jack, MD, DSc

    Peer

  11

  

  RestartResume

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients with CV Risks?

  0.25 credits

• • 

    

    Javed Butler, MD, MPH, MBA

    Peer

  7

  

  RestartResume

  Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy

  Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy

  0.25 credits

• • 

    

    Ewa A. Jankowska, MD, PhD, FESC

    Peer

  • 

    

    Stefan D. Anker, MD, PhD

    Peer

  16

  

  RestartResume

  Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

  Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency

  0.25 credits

• • 

    

    Robert J. Mentz, MD

    Peer

  • 

    

    Piotr Ponikowski, MD, PHD, FESC, FHFA

    Peer

  15

  

  RestartResume

  Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency

  Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency

  0.25 credits

• • 

    

    Sergio Fazio, MD, PhD

    Peer

  8

  

  RestartResume

  Practical Considerations to Manage Residual ASCVD Risk

  Practical Considerations to Manage Residual ASCVD Risk

  0.25 credits

• • 

    

    Ileana L. Piña, MD, MPH, FAHA, FACC

    Peer

  • 

    

    Javed Butler, MD, MPH, MBA

    Peer

  • 

    

    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA

    Peer

  14

  

  RestartResume

  Examining Heart Failure Management: How Can We Do Better?

  Examining Heart Failure Management: How Can We Do Better?

  0.25 credits

• • 

    

    Ileana L. Piña, MD, MPH, FAHA, FACC

    Peer

  • 

    

    Patrick Rossignol, MD, PhD

    Peer

  14

  

  RestartResume

  Potassium Binders in Heart Failure: Who, When, and How

  Potassium Binders in Heart Failure: Who, When, and How

  0.25 credits

• • 

    

    Prof. Stephen Nicholls

    Peer

  • 

    

    Prof. Kausik Ray

    Peer

  1

  

  RestartResume

  Examining LDL Cholesterol and Our Growing Therapy Options in Primary Prevention

  Examining LDL Cholesterol and Our Growing Therapy Options in Primary Prevention

• • 

    

    C. Michael Gibson, MD, MS

    Peer

  • 

    

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

    Peer

  • 

    

    Carolyn Lam, MD

    Peer

  2

  

  RestartResume

  Highlights from ACC.20/WCC Virtual Late-Breaker Session

  Highlights from ACC.20/WCC Virtual Late-Breaker Session

• • 

    

    Javed Butler, MD, MPH, MBA

    Peer

  • 

    

    John McMurray, OBE BSc (Hons) MB ChB (Hons) MD FRCP FESC FACC FAHA FRSE FMedSci

    Peer

  1

  

  RestartResume

  Clinical Implications of Heart Failure Trials Presented at the ACC.20/WCC Virtual Late-Breaker Session

  Clinical Implications of Heart Failure Trials Presented at the ACC.20/WCC Virtual Late-Breaker Session